Chronic pruritus: Targets, mechanisms and future therapies

Drug News and Perspectives

Volumn 21, Issue 10, 2008, Pages 541-551

  Pogatzki Zahn, Esther ^a   Marziniak, Martin ^a   Schneider, Gudrun ^a   Luger, Thomas A ^a   Ständer, Sonja ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CALCINEURIN INHIBITOR; CANNABINOID RECEPTOR AGONIST; CIMETIDINE; CYCLOSPORIN A; GABAPENTIN; GASTRIN RELEASING PEPTIDE RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MENTHOL; MONTELUKAST; MU OPIATE RECEPTOR ANTAGONIST; NALMEFENE; NALOXONE; NALTREXONE; PIMECROLIMUS; PREGABALIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ANALGESIC ACTIVITY; BEHAVIOR THERAPY; CASE STUDY; CENTRAL NERVOUS SYSTEM; CHRONIC DISEASE; CHRONIC PAIN; CLINICAL EFFECTIVENESS; CRYOTHERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MENTAL DISEASE; NERVE FIBER; NONHUMAN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRURITUS; PSYCHOEDUCATION; PSYCHOSOMATIC DISORDER; QUALITY OF LIFE; RELAXATION TRAINING; REVIEW; SOMATOSENSORY CORTEX; SPINAL CORD DORSAL HORN; TARGET CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIPRURITICS; BRAIN; CALCINEURIN; CANNABINOIDS; CENTRAL NERVOUS SYSTEM AGENTS; CHRONIC DISEASE; DERMATOLOGIC AGENTS; HUMANS; PRURITUS; SKIN; STRESS, PSYCHOLOGICAL;

EID: 62649133418     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2008.21.10.1314057     Document Type: Review

References (118)

1. Ikoma, A., Steinhoff, M., Stander, S., Yosipovitch, G. and Schmelz, M. The neurobiology of itch. Nat Rev Neurosci 2006, 7(7): 535-47.
2. Stander, S., Weisshaar, E., Mettang, T. et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007, 87(4): 291-4.
3. Stander, S., Streit, M., Darsow, U. et al. Diagnostic and therapeutic procedures in chronic pruritis. J Dtsch Dermatol Ges 2006, 4(4): 350-70.
4. Twycross, R., Greaves, M.W., Handwerker, H., Jones, E.A., Libretto, S.E. and Szepietowski, J.C., Zylicz, Z. Itch: scratching more than the surface. QJM 2003, 96(1): 7-26.
5. Stander, S. Rational symptomatic therapy for chronic pruritus. Hautarzt 2006, 57(5): 403-10.
6. Stander, S. and Schmelz, M. Chronic itch and pain - similarities and differences. Eur J Pain 2006, 10(5): 473-8.
7. Bromm, B., Scharein, E., Darsow, U. and Ring, J. Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neurosci Lett 1995, 187(3): 157-60.
8. Peier, A.M., Moqrich, A., Hergarden, A.C. et al. A TRP channel that senses cold stimuli and menthol. Cell 2002, 108(5): 705-15.
9. Story, G.M., Peier, A.M., Reeve, A.J. et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003, 112(6): 819-29.
10. Caterina, M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D. and Julius, D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389(6653): 816-24.
11. Zygmunt, P.M., Petersson, J., Andersson, D.A. et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400(6743): 452-7.
12. Jessell, T.M., Iversen, L.L. and Cuello, A.C. Capsaicin-induced depletion of substance P from primary sensory neurones. Brain Res 1978, 152(1): 183-8.
13. Stander, S., Moormann, C., Schumacher, M. et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol 2004, 13(3): 129-39.
14. Stander, S., Luger, T. and Metze, D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001, 44(3): 471-8.
15. Stander, S., Schmelz, M., Metze, D., Luger, T. and Rukwied, R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005, 38(3): 177-88.
16. Dvorak, M., Watkinson, A., McGlone, F. and Rukwied, R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 2003, 52(6): 238-45.
17. Rukwied, R., Watkinson, A., McGlone, F. and Dvorak, M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003, 102(3): 283-8.
18. Amaya, F., Shimosato, G., Kawasaki, Y., Hashimoto, S., Tanaka, Y., Ji, R.R. and Tanaka, M. Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 2006, 124(1-2): 175-83.
19. Farquhar-Smith, W.P. and Rice, A.S. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology 2003, 99(6): 1391-401.
20. Szepietowski, J.C., Reich, A. and Szepietowski, T. Emollients with endocannabinoids in the treatment of uremic pruritus: discussion of the therapeutic options. Ther Apher Dial 2005, 9(3): 277-9.
21. Szepietowski, J.C., Szepietowski, T. and Reich, A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat 2005, 13(2): 97-103.
22. Eberlein, B., Eicke, C., Reinhardt, H.W. and Ring, J. Adjuvant treatment of atopic eczema: Assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 2008, 22(1): 73-82.
23. Stander, S., Reinhardt, H.W. and Luger, T.A. Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus. Haularzt 2006, 57(9): 801-7.
24. Patwardhan, A.M., Jeske, N.A., Price, T.J., Gamper, N., Akopian, A.N. and Hargreaves, K.M. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid I (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A 2006, 103(30): 11393-8.
25. Faltore, L., Cossu, G., Spano, M.S., Deiana, S., Fadda, P., Scherma, M. and Fratta, W. Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol 2004, 16(1-2): 147-58.
26. Vigano, D., Rubino, T. and Parolaro, D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 2005, 81(2): 360-8.
27. Ibrahim, M.M., Porreca, F., Lai, J. et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 2005, 102(8): 3093-8.
28. Senba, E., Katanosaka, K., Yajima, H. and Mizumura, K. The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. Neurosci Res 2004, 50(3): 257-62.
29. Stander, S., Stander, H., Seeliger, S., Luger, T.A. and Steinhoff, M. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol 2007, 156(5): 1020-6.
30. Stander, S., Schurmeyer-Horst, F., Luger, T.A. and Weisshaar, E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag 2006, 2(2): 213-8.
31. Darsow, U., Scharein, E., Bromm, B. and Ring, J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumour necrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol 1997, 137(3): 415-7.
32. Martin, H.A. and Murphy, P.R. Interleukin-2 activates a sub-population of cutaneous C-fibre polymodal nociceptors in the rat hairy skin. Arch Physiol Biochem 1995, 103(2): 136-48.
33. Martin, H.A. Bradykinin potentiates the chemoresponsiveness of rat cutaneous C-fibre polymodal nociceptors to interleukin-2. Arch Physio] Biochem 1996, 104(2): 229-38.
34. Wahlgren, C.F., Scheynius, A. and Hagermark, O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 1990, 70(4): 323-9.
35. Andrew, D. and Craig, A.D. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001, 4(1): 72-7.
36. Siepmann, D., Luger, T.A. and Stander, S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: Results of a case series. J Dtsch Dermatol Ges 2008, 6(11): 941-6.
37. Hill, S.J. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev 1990, 42(1): 45-83.
38. Gelfand, E.W., Appajosyula, S. and Meeves, S. Anti-inflammatory activity of III-receptor antagonists: Review of recent experimental research. Curr Med Res Opin 2004, 20(1): 73-81.
39. Andoh, T. and Kuraishi, Y. Inhibitory effects of azelastine on substance P-induced itch-associated response in mice. Eur J Pharmacol 2002, 436(3): 235-9.
40. Amsellem, C., Czarlewski, W., Lagarde, M. and Pacheco, Y. Inhibitory effect of loratadine on leukotriene B4 production by neutrophils either alone or during interaction with human airway epithelial cells. Pulm Pharmacol Ther 1998, 11(4): 245-52.
41. Schroeder, J.T., Schleimer, R.P., Lichtenstein, L.M. and Kreutner, W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001, 31(9): 1369-77.
42. Lippert, U., Kruger-Krasagakes, S., Moller, A., Kiessling, U. and Czarnetzki, B.M. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995, 4(4 Pt 2): 272-6.
43. Wu, P., Mitchell, S. and Walsh, G.M. A new antihistamine levocetirizine inhibits eosinophil adhesion to vascular cell adhesion molecule-1 under flow conditions. Clin Exp Allergy 2005, 35(8): 1073-9.
44. Giustizieri, M.L., Albanesi, C., Fluhr, J., Gisondi, P., Norgauer, J. and Girolomoni, G. H1 histamine receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol 2004, 114(5): 1176-82.
45. Vancheri, C., Mastruzzo, C., Tomaselli, V. et al. The effect of fexofenadine on expression of intercellular adhesion molecule I and induction of apoptosis on peripheral eosinophils. Allergy Asthma Proc 2005, 26(4): 292-8.
46. Gillard, M. and Chatelain, P. Changes in pH differently affect the binding properties of histamine H1 receptor antagonists. Eur J Pharmacol 2006, 530(3): 205-14.
47. Bell, J.K., McQueen, D.S. and Rees, J.L. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br J Pharmacol 2004, 142(2): 374-80.
48. Aymard, J.P., Lederlin, P., Witz, F., Colomb, J.N., Herbeuval, R. and Weber, B. Cimetidine for pruritus in Hodgkin's disease. Br Med J 1980, 280(6208): 151-2.
49. Weick, J.K., Donovan, P.B., Najean, Y., Dresch, C., Pisciotta, A.V., Cooperberg, A.A. and Goldberg, J.D. The use of cimetidine for the treatment of pruritus in polycythemia vera. Arch Intern Med 1982, 142(2): 241-2.
50. Andoh, T. and Kuraishi, Y. Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in-mice. Eur J Pharmacol 1998, 353(1): 93-96.
51. Miyoshi, M., Sakurai, T., Kodama, S. Clinical evaluation of urinary leukotriene E4 levels in children with atopic dermatitis. Arerugi 1999, 48(10): 1148-52.
52. Di Lorenzo, G., Pacor, M.L., Mansueto, P. et al. Is there a role for antileukotrienes in urticaria? Clin Exp Dermatol 2006, 31(3): 327-34.
53. Bernardini, N., Roza, C., Sauer, S.K., Gomeza, J., Wess, J. and Reeh, P.W. Muscarinic M2 receptors on peripheral nerve endings: A molecular target of antinociception. J Neurosci 2002, 22(12): RC229.
54. Carucci, J.A., Washenik, K., Weinstein, A., Shupack, J. and Cohen, D.E. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998, 134(7); 785-6.
55. Woodmansee, D.P. and Simon,R.A. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999, 83(6 Pt I): 548-52.
56. Zabawski, E.J. Jr, Kahn, M.A. and Gregg, L.J. Treatment of atopic dermatitis with zafirlukast. Dermatol Online J 1999, 5(2): 10.
57. Paus, R., Schmelz, M., Biro, T., and Steinhoff, M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2006, 116(5): 1174-86.
58. Schmelz, M., Schmidt, R., Bickel, A., Handwerker, H.O. and Torebjork, H.E. Specific C-receptors for itch in human skin. J Neurosci 1997, 17(20): 8003-8.
59. Schmidt, R., Schmelz, M., Ringkamp, M., Handwerker, H.O. and Torebjork, H.E. Innervation territories of mechanically activated C nociceptor units in human skin. J Neurophysiol 1997, 78(5): 2641-8.
60. Schmelz, M., Schmidt, R., Weidner, C., Hilliges, M., Torebjork, H.E. and Handwerker, H.O. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol 2003, 89(5): 2441-8.
61. Ikoma, A., Handwerker, H., Miyachi, Y. and Schmelz, M. Electrically evoked itch in humans. Pain 2005, 113(1-2): 148-54.
62. Johanek, L.M., Meyer, R.A., Hartke, T., Hobelmann, J.G., Maine, D.N., LaMotte, R.H. and Ringkamp, M. Psychophysical and physiological evidence for parallel afferent pathways mediating the sensation of itch. J Neurosci 2007, 27: 7490-7.
63. Reddy, V.B., Iuga, A.O., Shimada, S.G., LaMotte, R.H. and Lerner, E.A. Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease activated receptors. J Neurosci 2008, 28: 4331-5.
64. Steinhoff, M., Neisius, U., Ikoma, A. et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003, 23: 6176-80.
65. Craig, A.D. How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev Neurosci 2002, 3(8): 655-66.
66. Sun, Y.G. and Chen, Z.F. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007, 448(7154): 700-3.
67. Davidson, S., Zhang, X., Yoon, C.H., Khasabov, S.G., Simone, D.A. and Giesler, G.J. Jr. The itch producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. J Neurosci 2007, 27: 10007-14.
68. Rees, J.L. and Laidlaw, A. Pruritus: More scratch than itch. Clin Exp Dermatol 1999, 24(6): 490-3.
69. Hsieh, J.C., Hagermark, O., Stahle-Backdahl, M., Ericson, K., Eriksson, L., Stone-Elander, S. and Ingvar, M. Urge to scratch represented in the human cerebral cortex during itch. J Neurophysiol 1994, 72(6): 3004-8.
70. Drzezga, A., Darsow, U., Treede, R.D. et al. Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H2O positron emission tomography studies. Pain 2001, 92(1-2): 295-305.
71. Mochizuki, H., Tashiro, M., Kano, M., Sakurada, Y., Itoh, M. and Yanai, K. Imaging of central itch modulation in the human brain using positron emission tomography. Pain 2003, 105(1-2): 339-16.
72. Schneider, G., Ständer, S., Burgmer, M., Driesch, G., Heuft, G. and Weckesser, M. Significant differences in central imaging of histamine-induced itch between atopic dermatitis and healthy subjects. Eur J Pain 2008, 12(7): 834-41.
73. Nilsson, H.J., Levinsson, A. and Schouenborg, J. Cutaneous field stimulation (CFS): a new powerful method to combat itch. Pain 1997, 71: 49-55.
74. Yosipovitch, G., Duque, M.I., Fast, K., Dawn, A.G. and Coghill, R.C. Scratching and noxious heat stimuli inhibit itch in humans: A psychophysical study. Br J Dermatol 2007, 156(629): 634.
75. McRae, C.A., Prince, M.I., Hudson, M., Day, C.P., James, O.F. and Jones, D.E. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003, 125: 591-6.
76. Kamei, J. and Nagase, H. Norbinaltorphimine, a selective j-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol 2001, 418: 141-5.
77. Kjellberg, F. and Tramer, M.R. Pharmacological control of opioid-induced pruritus: A quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001, 18: 346-57.
78. Behbehani, M.M. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 1995, 46(6): 575-605.
79. Carstens, E. Responses of rat spinal dorsal horn neurons to intracutaneous microinjection of histamine, capsaicin, and other irritants. J Neurophysiol 1997, 77(5): 2499-514.
80. Bickford, R.G.L. Experiments relating to itch sensation, its peripheral mechanism and central pathways. Clin Sci 1938, 3: 377-86.
81. Simone, D.A., Alreja, M. and LaMotte, R.H. Psychophysical studies of the itch sensation and itchy skin ("alloknesti") produced by intracutaneous injection of histamine. Somatosens Mot Res 1991, 8: 271-9.
82. Atanassoff, P.G., Brull, S.J., Zhang, J., Greenquist, K., Silverman, D.G. and LaMotte, R.H. Enhancement of experimental pruritus and mechanically evoked dysesthesiae with local anesthesia. Somatosens Mot Res 1999, 16: 291-8.
83. Grewe, M., Vogelsang, K., Ruzicka, T., Stege, H. and Krutmann, J. Neurotrophin-4 production by human epidermal keratinocytes: Increased expression in atopic dermatitis. J Invest Dermatol 2000, 114(6): 1108-12.
84. Woolf, C.J., Safieh-Garabedian, B., Ma, Q.P., Crilly, P. and Winter, J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 1994, 62(2): 327-31.
85. Toyoda, M., Nakamura, M., Makino, T., Hino, T., Kagoura, M. and Morohashi, M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 2002, 147(1): 71-9.
86. Heppenstall, P.A. and Lewin, G.R. Neurotrophins, nociceptors and pain. Curr Opin Anaesthesiol 2000, 13(5): 573-6.
87. Yesudian, P.D. and Wilson, N.J. Efficacy of gabapentin in the management of pruritus of unknown origin. Arch Dermatol 2005, 141(12): 1507-9.
88. Schurmeyer-Horst, F., Fischbach, R., Nabavi, D., Metze, D. and Stander, S. Brachioradial pruritus: a rare, localized, neuropathic form of itching. Hautarzt 2006, 57(6): 523-7.
89. Ben-Menachem, E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004, 45 Suppl: 613-8.
90. Wedekind, D. and Bandelow, B. The alpha2delta subunit of the voltage-dependent calcium channel. A new pharmaceutical target for psychiatry and neurology. Nervenarzt 2005, 76(7): 888-91.
91. Metze, D., Reimann, S., Beissert, S. and Luger, T. Efficacy and safety of naltrexone, an oral opiate recepter antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999, 41(4): 533-9.
92. Metze, D., Reimann, S. and Luger, T.A. Effective treatment of pruritus with naltrexone, an orally active opiate antagonist. Ann N Y Acad Sci 1999, 88(5): 430-2.
93. Bergasa, N.V., Alling, D.W., Talbot, T.L., Wells, M.C. and Jones, E.A. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999, 41(3 Pt 1): 431-4.
94. Mansour-Ghanaei, F., Taheri, A., Froutan, H., et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006, 12(7): 1125-8.
95. Monroe, E.W. Efficacy and safety of nalmefene in patients with severe pruritis caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 1989, 21(1): 135-6.
96. Brune, A., Metze, D., Luger, T.A. and Stander, S. Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients. Hautarzt 2004, 55(12): 1130-6.
97. Tefferi, A. and Fonseca, R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Bloods 2002, 99(7): 2627.
98. Zylicz, Z., Krajnik, M., Sorge, A.A. and Costantini, M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003, 26(6): 1105-12.
99. Zylicz, Z., Smits, C. and Krajnik, M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998, 16(2): 121-4.
100. Duman, E.N., Kesim, M., Kadioglu, M., Yaris, E., Kalyoncu, N.I. and Erciyes, N. Possible involvement of opioidergic and serotonergic mechanics in antinociceptive effect of paroxetine in acute pain. J Pharmacol Sci 2004, 94(2): 161-5.
101. Mayo, M.J., Handem, I., Saldana, S., Jacobe, H., Getachew, Y. and Rush, A.J. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007, 45(3): 666-74.
102. Ständer, S., Böckenholt, B., Schürmeyer-Horst, F., Heuft, G., Luger, T.A. and Schneider, G. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: Results of an open-labeled, two-arm proof-of-concept study. Acta DermatoVenereol 2008, in press.
103. Muller, C., Pongratz, S., Pidlich, J. et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: A randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Mepatol 1998, 10(10): 865-70.
104. Schworer, H., Hartmann, H., Ramadori, G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995, 61(1): 33-7.
105. Weisshaar, E., Dunker, N., Domrose, U., Neumann, K.H. and Gollnick, H. Plasma serotonin and histamine levels in hemodialysis-related pruritus are not significantly influenced by 5-HT3 receptor blocker and antihistaminic therapy. Clin Nephrol 2003, 59(2): 124-9.
106. Zhang, X., Huang, J. and McNaughton, P.A. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 2005, 24(24): 4211-23.
107. Schneider, G. and Gieler, U. Die Haut als Spiegel der Seele. Psychosomatische Dermatologie - aktueller Forschungsstand. Z Psychosom Med Psychother 2001, 47: 307-31.
108. Schneider, G., Hockmann, J., Ständer, S., Luger, A.T. and Heuft, G. Psychological factors in prurigo nodularis in comparison with psoriasis vulgaris - results of a case-control study. Br J Dermatol 2006, 154: 61-6.
109. Schneider, G., Driesch, G., Heuft, G., Evers, S., Luger, T.A. and Ständer, S. Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch. Clin Exp Dermatol 2006, 31: 762-7.
110. Capoore, H.S., Rowland-Payne, C.M.E. and Goldin, D. Does psychological intervention help chronic skin conditions? Postgrad Med J 1998, 74: 662-1.
111. Johansson, O., Liang, Y. and Emtestam, L. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin - an exploration of the cause of neurohyperplasia. Arch Dermatol Res 2002, 293(12): 614-9.
112. Obreja, O., Rukwied, R., Steinhoff, M. and Schmelz, M. Neurogenic components of trypsin- and thrombin-induced inflammation in rat skin, in vivo. Exp Dermatol 2006, 15(1): 58-65.
113. Ui, H., Andoh, T., Lee, J.B., Nojima, H. and Kuraishi, Y. Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. Eur J Pharmacol 2006, 530(1-2): 172-8.
114. Steinhoff, M., Vergnolle, N., Young, S.H. et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med. 2000, 6(2): 151-8.
115. Takaoka, A., Arai, I., Sugimoto, M., Honma, Y., Futaki, N., Nakamura, A. and Nakaike, S. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol 2006, 15(3): 161-7.
116. Schulz, F., Marenholz, I., Folster-Holst, R. et al. A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. J Allergy Clin Immunol 2007, 120(5): 1097-102.
117. Neis, M.M., Peters, B., Dreuw, A. et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006, 118(4): 930-7.
118. Sonkoly, E., Muller, A., Lauerma, A.I. et al. IL-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117(2): 411-7.